Biotech · Public company · South San Francisco, CA, US
IDEAYA Biosciences, Inc.
Ticker IDYA · SEC CIK 0001676725
Track this companyFree. Adds IDEAYA Biosciences, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials1212 recruiting or active
Pipeline programs23From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline23
- CrizotinibPhase 3 · Metastatic Uveal MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- Crizotinib (Xalkori)Phase 3 · Uveal MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- DacarbazinePhase 3 · Metastatic Uveal MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- DarovasertibPhase 3 · Uveal MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- IDE196Phase 3 · Metastatic Uveal MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- IpilimumabPhase 3 · Metastatic Uveal MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 3 · Metastatic Uveal MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 3 · Metastatic Uveal MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- Primary Local TherapyPhase 3 · Uveal MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- BinimetinibPhase 2 · Metastatic Uveal MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 2 · Small-cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- durvalumabPhase 2 · Small-cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- IDE161Phase 2 · Small-cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- IDE849Phase 2 · Small-cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Fulvestrant injectionPhase 1 · CancerClinicalTrials.gov · fetched Nov 12, 2026
- IDE-161Phase 1 · Advanced or Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- IDE034Phase 1 · Esophageal Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- IDE397Phase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- IDE397Phase 1 · NSCLC AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- IDE574Phase 1 · CancerClinicalTrials.gov · fetched Nov 12, 2026
- IDE892Phase 1 · NSCLC AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 1 · Advanced or Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- Sacituzumab govitecanPhase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials12
- Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal MelanomaPHASE3 · RECRUITING · started Sep 1, 2026ClinicalTrials.gov NCT07804186 · fetched Nov 12, 2026
- A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid TumorsPHASE1 · RECRUITING · started Mar 17, 2026ClinicalTrials.gov NCT07540572 · fetched Nov 12, 2026
- A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid TumorsPHASE1 · RECRUITING · started Mar 4, 2026ClinicalTrials.gov NCT07277413 · fetched Nov 12, 2026
- A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesPHASE1 · RECRUITING · started Feb 24, 2026ClinicalTrials.gov NCT07503808 · fetched Nov 12, 2026
- Neoadjuvant Darovasertib in Primary Uveal MelanomaPHASE3 · RECRUITING · started Jan 25, 2026ClinicalTrials.gov NCT07015190 · fetched Nov 12, 2026
- A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung CancerPHASE1_PHASE2 · RECRUITING · started Oct 14, 2025ClinicalTrials.gov NCT07174583 · fetched Nov 12, 2026
- A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid TumorsPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Dec 13, 2024ClinicalTrials.gov NCT06710847 · fetched Nov 12, 2026
- IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaPHASE2_PHASE3 · ACTIVE_NOT_RECRUITING · started Oct 31, 2023ClinicalTrials.gov NCT05987332 · fetched Nov 12, 2026
- (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular MelanomaPHASE2 · ACTIVE_NOT_RECRUITING · started Jul 3, 2023ClinicalTrials.gov NCT05907954 · fetched Nov 12, 2026
- A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsPHASE1 · ACTIVE_NOT_RECRUITING · started Apr 18, 2023ClinicalTrials.gov NCT05787587 · fetched Nov 12, 2026
- Study of IDE397 in Participants With Solid Tumors Harboring MTAP DeletionPHASE1 · ACTIVE_NOT_RECRUITING · started Apr 14, 2021ClinicalTrials.gov NCT04794699 · fetched Nov 12, 2026
- Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC FusionsPHASE1_PHASE2 · RECRUITING · started Jun 28, 2019ClinicalTrials.gov NCT03947385 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 3, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 3, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 23, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 3, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 1, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 5, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 13, 2026 · fetched Nov 12, 2026